PT - JOURNAL ARTICLE AU - L.J. Krüger AU - M. Gaeddert AU - L. Köppel AU - L. E. Brümmer AU - C. Gottschalk AU - I.B. Miranda AU - P. Schnitzler AU - H.G. Kräusslich AU - A.K. Lindner AU - O. Nikolai AU - F.P. Mockenhaupt AU - J. Seybold AU - V.M. Corman AU - C. Drosten AU - N.R. Pollock AU - A.I. Cubas-Atienzar AU - K. Kontogianni AU - A. Collins AU - A. H. Wright AU - B. Knorr AU - A. Welker AU - M. de Vos AU - J.A. Sacks AU - E.R. Adams AU - C.M. Denkinger AU - for the study team TI - Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for <em>SARS-CoV-2</em> AID - 10.1101/2020.10.01.20203836 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.01.20203836 4099 - http://medrxiv.org/content/early/2020/10/04/2020.10.01.20203836.short 4100 - http://medrxiv.org/content/early/2020/10/04/2020.10.01.20203836.full AB - Background Reliable point-of-care (POC) diagnostics not requiring laboratory infrastructure could be a game changer in the COVID-19 pandemic, particularly in the Global South. We assessed performance, limit of detection and ease-of-use of three antigen-detecting, rapid POC tests (Ag-RDT) for SARS-CoV-2.Methods This prospective, multi-centre diagnostic accuracy study recruited participants suspected to have SARS-CoV-2 in Germany and the UK. Paired nasopharyngeal swabs (NP) or NP and/or oropharyngeal swabs (OP) were collected from participants (one for clinical RT-PCR and one for Ag-RDT). Performance of each of three Ag-RDTs was compared to RT-PCR overall, and according to predefined subcategories e.g. cycle threshold (CT)-value, days from symptoms onset, etc. In addition, limited verification of the analytical limit-of-detection (LOD) was determined. To understand the usability a System Usability Scale (SUS) questionnaire and ease-of-use (EoU) assessment were performed.Results Between April 17th and August 25th, 2020, 2417 participants were enrolled, with 70 (3.0%) testing positive by RT-PCR. The best-performing test (SD Biosensor, Inc. STANDARD Q) was 76×6% (95% Confidence Interval (CI) 62×8-86×4) sensitive and 99×3% (CI 98×6-99×6) specific. A sub-analysis showed all samples with RT-PCR CT-values &lt;25 were detectable by STANDARD Q. The test was considered easy-to-use (SUS 86/100) and suitable for POC. Bioeasy and Coris showed specificity of 93×1% (CI 91×0%-94×8%) and 95×8% (CI 93×4%-97×4%), respectively, not meeting the predefined target of ≥98%.Conclusion There is large variability in performance of Ag-RDT with SD Biosensor showing promise. Given the usability at POC, this test is likely to have impact despite imperfect sensitivity; however further research and modelling are needed.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialGerman Clinical Trial Registry DRKS00021220Clinical Protocols https://apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00021220 Funding StatementThe study was supported by FIND, Heidelberg University Hospital and Charite University Hospital internal funds. Pfizer funded the clinical team in Liverpool, UK. The external funders of the study had no role in study design, data collection, or data analysis. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethical review committee at the University Hospital Heidelberg for the study sites in Heidelberg and Berlin (Registration number S-180/2020), and by the NHS review board, IRAS number 282147, for the study in Liverpool, UK. Each participant provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be available upon request.